Cambridge Healthtech Institute’s Third Annual

Cancer Biotherapeutics
5-6 November 2015


Research this year indicates rapid growth in the field of immunotherapy, and developments with bispecifics and other novel products, ADCs, and combination approaches.

I am interested in talks that describe platform development together with engineering challenges, mode of action and advantages over other approaches. Presentations should include safety and management of toxicity. I intend to cover new emerging targets, reasons for choice of target, and applicability to different cancers. Preclinical and clinical data will also be included such as proof of concept, translational biomarkers, and IND enabling studies. In addition, I am looking for information on properties such as half-life, PKPD, solubility, formulation, stability, manufacturability, and how the drug is administered to the patient.

Topics will include, but are not limited to, the following: 

A range of immunotherapy approaches including: 

  • Immune check point inhibitors: Developments with targeting PD-1 and PD-L1 and other check point proteins regarding optimization of treatment, safety concerns and extrapolation to cancers other than melanoma.
  • Targeting T and other immune response cells such as macrophages, dendritic cells and NK cells; Targeting CD3 and/or the T cell MHC complex in combination with cancer targets.
  • CAR: Developments with engineered chimeric antigen receptor-engineered T cells. I’m looking for talks that focus on efficient transfection, the speed of the process and management of toxicity.

Developments with ADCs 

  • Conjugation strategies including site-specific conjugation, novel payloads, critical issues for taking ADCs into the clinic and building an IND, and measures to reduce toxicity.

Novel Engineering Approaches 

  • Developments with bi and multi-specific antibodies for cancer
  • Novel or unusual targets such ones for cell proliferation, angiogenesis and metastasis
  • Fc Engineering to Enhance Complement Activation
  • Fusion Proteins
  • Clinical data

Combination Approaches 

  • For example bispecifics and ADCs in combination, antibodies with chemotherapy, and antibodies with cell-based therapies such as TCRs. I would like to include synergistic approaches, challenges with getting the right balance, and advantages over single therapy approaches.

If you would like to submit a proposal to give a presentation at this meeting, please click here.

Deadline for submission is 30 March 2015 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489
Email: nlyscom@healthtech.com 

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471
Email: dinerstein@healthtech.com 

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452
Email: jgerardi@healthtech.com